Article Text

Download PDFPDF
Uterus transplantation in women who are genetically XY
  1. Amani Sampson1,
  2. Laura L. Kimberly2,3,
  3. Kara N. Goldman1,
  4. David L. Keefe1,
  5. Gwendolyn P. Quinn1,3
  1. 1 Department of Obstetrics and Gynecology, New York University School of Medicine, New York City, New York, USA
  2. 2 Hansjörg Wyss Department of Plastic Surgery, New York University School of Medicine, New York City, New York, USA
  3. 3 Division of Medical Ethics, Department of Population Health, New York University School of Medicine, New York City, New York, USA
  1. Correspondence to Dr Gwendolyn P. Quinn, Obstetrics and Gynecology, NYU School of Medicine, New York NY 10016, USA; gwendolyn.quinn{at}


Uterus transplantation is an emerging technology adding to the arsenal of treatments for infertility; specifically the only available treatment for uterine factor infertility. Ethical investigations concerning risks to uteri donors and transplant recipients have been discussed in the literature. However, missing from the discourse is the potential of uterus transplantation in other groups of genetically XY women who experience uterine factor infertility. There have been philosophical inquiries concerning uterus transplantation in genetically XY women, which includes transgender women and women with complete androgen insufficiency syndrome. We discuss the potential medical steps necessary and associated risks for uterus transplantation in genetically XY women. Presently, the medical technology does not exist to make uterus transplantation a safe and effective option for genetically XY women, however this group should not be summarily excluded from participation in trials. Laboratory research is needed to better understand and reduce medical risk and widen the field to all women who face uterine factor infertility.

  • sexuality/gender
  • reproductive medicine
  • transplantation
  • ethics
  • obstetrics and gynaecology

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors All authors contributed equally to the development and writing of the case.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Patient consent for publication Not required.